Preparation and Bioavailability Assessment of SMEDDS Containing Valsartan

被引:134
作者
Dixit, Adhvait R. [1 ,2 ]
Rajput, Sadhana J. [1 ]
Patel, Samir G. [1 ]
机构
[1] Maharaja Sayajirao Univ Baroda, Dept Pharm, Vadodara, Gujarat, India
[2] Dr Reddys Labs Ltd, IPDO, Qutubullpur 500072, Andhra Pradesh, India
关键词
bioavailability; particle size; SMEDDS; valsartan; zeta potential; DRUG-DELIVERY SYSTEM; ORAL ABSORPTION; DESIGN; FORMULATIONS; ENHANCEMENT;
D O I
10.1208/s12249-010-9385-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A self-microemulsifying drug delivery system (SMEDDS) has been developed to enhance diffusion rate and oral bioavailability of valsartan. The solubility of valsartan was checked in different oils, surfactants, and cosurfactants and ternary phase diagrams were constructed to evaluate the microemulsion domain. The valsartan SMEDDS was prepared using Capmul MCM (oil), Tween 80 (surfactant), and polyethylene glycol 400 (cosurfactant). The particle size distribution, zeta potential, and polydispersity index were determined and were found to be 12.3 nm, -0.746, and 0.138, respectively. Diffusion rate of valsartan was measured by in vitro dialysis bag method using phosphate buffer pH 6.8 as diffusion media. Developed high-performance liquid chromatography method was used to determine drug content in diffusion media. Oral bioavailability of valsartan SMEDDS was checked by using rabbit model. Results of diffusion rate and oral bioavailability of valsartan SMEDDS were compared with those of pure drug solution and of marketed formulation. Diffusion of valsartan SMEDDS showed maximum drug release when compared to pure drug solution and marketed formulation. The area under curve and time showed significant improvement as the values obtained were 607 ng h/mL and 1 h for SMEDDS in comparison to 445.36 and 1.36 h for market formulation suggesting significant increase (p < 0.01) in oral bioavailability of valsartan SMEDDS.
引用
收藏
页码:314 / 321
页数:8
相关论文
共 27 条
[1]  
Baboota Sanjula, 2007, Acta Pharmaceutica (Zagreb), V57, P315, DOI 10.2478/v10007-007-0025-5
[2]   Pharmacokinetics of valsartan in patients with liver disease [J].
Brookman, LJ ;
Rolan, PE ;
Benjamin, IS ;
Palmer, KR ;
Wyld, PJ ;
Lloyd, P ;
Flesch, G ;
Waldmeier, F ;
Sioufi, A ;
Mullins, F .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (03) :272-278
[3]   Improvement of solubility and stability of valsartan by hydroxypropyl-β-cyclodextrin [J].
Cappello, Brunella ;
Di Maio, Clelia ;
Iervolino, Maria ;
Miro, Agnese .
JOURNAL OF INCLUSION PHENOMENA AND MACROCYCLIC CHEMISTRY, 2006, 54 (3-4) :289-294
[4]  
Charman WN, 2000, J PHARM SCI-US, V89, P967, DOI 10.1002/1520-6017(200008)89:8<967::AID-JPS1>3.0.CO
[5]  
2-R
[6]   TRANSPORT OF LIPOPHILIC MOLECULES BY THE INTESTINAL LYMPHATIC-SYSTEM [J].
CHARMAN, WN ;
STELLA, VJ .
ADVANCED DRUG DELIVERY REVIEWS, 1991, 7 (01) :1-14
[7]   LIPID MICROEMULSIONS FOR IMPROVING DRUG DISSOLUTION AND ORAL ABSORPTION - PHYSICAL AND BIOPHARMACEUTICAL ASPECTS [J].
CONSTANTINIDES, PP .
PHARMACEUTICAL RESEARCH, 1995, 12 (11) :1561-1572
[8]   Enhancement of oral absorption of curcumin by self-microemulsifying drug delivery systems [J].
Cui, Jing ;
Yu, Bo ;
Zhao, Yu ;
Zhu, Weiwei ;
Li, Houli ;
Lou, Hongxiang ;
Zhai, Guangxi .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2009, 371 (1-2) :148-155
[9]   Design and evaluation of self-nanoemulsifying drug delivery systems (SNEDDS) for cefpodoxime proxetil [J].
Date, Abhijit A. ;
Nagarsenker, M. S. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2007, 329 (1-2) :166-172
[10]   Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs [J].
Gershanik, T ;
Benita, S .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2000, 50 (01) :179-188